ADPT Share Price Performance
US$18.61
13.92 (296.80%)
2.8% undervalued intrinsic discount
US$19.14
Fair Value
Price US$18.61
AnalystConsensusTarget US$19.14
AnalystHighTarget US$15.00
Fair ValueUS$19.14
Share Pricen/a
Adaptive Biotechnologies Corporation Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ADPT Community Narratives
AN
Fair Value US$19.14 2.8% undervalued intrinsic discount
ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$15 24.1% overvalued intrinsic discount
Precision Medicine And Immune Sequencing Will Expand Diagnostic Horizons
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks
Key Takeaways Expansion of clonoSEQ integration and higher reimbursement rates position the company for strong recurring revenue growth and improved gross margins. Advances in clinical and AI-driven immune medicine pipelines create future opportunities in pharma partnerships and innovative diagnostics, supporting long-term earnings potential.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$19.14
2.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
14.01% p.a.
Profit Margin
15.7%
Future PE
68.81x
Share price in 2028
US$23.93
Precision Medicine And Immune Sequencing Will Expand Diagnostic Horizons
Key Takeaways Rapid payer adoption and expanded coverage for clonoSEQ are driving significant revenue and margin growth beyond market expectations. Leadership in innovative diagnostics and expanding indications are diversifying revenue streams, supporting sustained test growth and long-term financial upside.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15
24.1% overvalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
23.42% p.a.
Profit Margin
14.21%
Future PE
56.65x
Share price in 2028
US$18.56
Recently Updated Narratives
AN
ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks
Fair Value: US$19.14 2.8% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Precision Medicine And Immune Sequencing Will Expand Diagnostic Horizons
Fair Value: US$15 24.1% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Adaptive Biotechnologies Corporation Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.52
- 65.08%
- -31.50%
- 64.5%
About ADPT
- Founded
- 2009
- Employees
- 619
- CEO
- WebsiteView website
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
